Oxurion NV (OXUR.BR)

EUR 0.08

(-2.44%)

Revenue Summary of Oxurion NV

  • Oxurion NV's latest annual revenue in 2023 was 263 Thousand EUR , down -55.8% from previous year.
  • Oxurion NV's latest quarterly revenue in 2024 Q2 was 1000.00 EUR , down 0.0% from previous quarter.
  • Oxurion NV reported a annual revenue of 595 Thousand EUR in annual revenue 2022, down -47.25% from previous year.
  • Oxurion NV reported a annual revenue of 1.12 Million EUR in annual revenue 2021, down -45.72% from previous year.
  • Oxurion NV reported a quarterly revenue of 180 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • Oxurion NV reported a quarterly revenue of 83 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Revenue Chart of Oxurion NV (2023 - 2006)

Historical Annual Revenue of Oxurion NV (2023 - 2006)

Year Revenue Revenue Growth
2023 263 Thousand EUR -55.8%
2022 595 Thousand EUR -47.25%
2021 1.12 Million EUR -45.72%
2020 2.07 Million EUR -47.34%
2019 3.94 Million EUR -25.83%
2018 5.32 Million EUR -8.43%
2017 5.81 Million EUR -18.22%
2016 7.1 Million EUR -36.56%
2015 11.19 Million EUR -18.71%
2014 13.77 Million EUR -87.79%
2013 112.78 Million EUR 50.21%
2012 75.08 Million EUR 2932.43%
2011 2.47 Million EUR -59.9%
2010 6.17 Million EUR 46.57%
2009 4.21 Million EUR -86.15%
2008 30.42 Million EUR 2329.79%
2007 1.25 Million EUR -61.39%
2006 3.24 Million EUR 0.0%

Peer Revenue Comparison of Oxurion NV

Name Revenue Revenue Difference
Nicox S.A. 257 Thousand EUR -2.335%
European Medical Solutions 40.56 Million EUR 99.352%
FERMENTALG 4.05 Million EUR 93.517%
argenx SE 1.13 Billion EUR 99.977%
BioSenic S.A. 543 Thousand EUR 51.565%
Celyad Oncology SA 102 Thousand EUR -157.843%
Hyloris Pharmaceuticals SA 2.08 Million EUR 87.398%
Onward Medical N.V. 532 Thousand EUR 50.564%
PHAXIAM Therapeutics S.A. 1.32 Million EUR 80.166%
Financière de Tubize SA - EUR -Infinity%
UCB SA 5.25 Billion EUR 99.995%